Revolutionary cancer therapies are no longer confined to science fiction. Dr. Michael Baker, CEO of Arovella Therapeutics (ASX: ALA), reveals how the company's groundbreaking work with invariant natural killer T-cells (iNKT cells) is transforming cancer treatment through truly off-the-shelf cell therapies.
Dr Michael Baker interview with ASX Briefs
Previous
Previous
Arovella Receives R&D Tax Rebate of $3,210,000
Next
Next